4.39

0.45% -0.02

Voyager Therapeutics Inc (VYGR)

Overview News Price History Option Chain Financials Discussions Forecast

Voyager Therapeutics Inc stock is traded at $4.39, with a volume of 257.53K. It is down -0.45% in the last 24 hours and up +3.29% over the past month. Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Previous Close:

$4.41

Open:

$4.41

24h Volume:

257.53K

Relative Volume:

0.41

Market Cap:

$244.08M

Revenue:

$163.78M

Net Income/Loss:

$25.88M

P/E Ratio:

6.7538

EPS:

0.65

Net Cash Flow:

$-28.66M

1W Performance:

+2.57%

1M Performance:

+3.29%

6M Performance:

+21.94%

1Y Performance:

-29.76%

1-Day Range:

$4.35

$4.46

1-Week Range:

$4.2315

$4.512

52-Week Range:

$2.645

$6.55

Voyager Therapeutics Inc Stock (VYGR) Company Profile

Name

Voyager Therapeutics Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

857-259-5340

Address

75 HAYDEN AVENUE, LEXINGTON, MA

Employee

172

Twitter

@VoyagerTx

Next Earnings Date

2025-03-11

Latest SEC Filings

VYGR's Discussions on Twitter

Compare VYGR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VYGR Voyager Therapeutics Inc	4.39	245.20M	163.78M	25.88M	-28.66M	0.65
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Dec-02-24	Initiated	Citigroup	Buy
Nov-29-24	Resumed	Wedbush	Outperform
Oct-16-24	Initiated	Leerink Partners	Outperform
Mar-26-24	Initiated	Guggenheim	Buy
Mar-19-24	Initiated	H.C. Wainwright	Buy
Mar-07-24	Initiated	Citigroup	Buy
Jan-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight
May-10-23	Initiated	Truist	Buy
Mar-10-23	Initiated	Oppenheimer	Outperform
Oct-07-21	Upgrade	Robert W. Baird	Neutral → Outperform
Feb-26-21	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-03-21	Downgrade	BTIG Research	Buy → Neutral
Feb-03-21	Downgrade	Wedbush	Outperform → Neutral
Dec-24-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-23-20	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Downgrade	Oppenheimer	Outperform → Perform
Nov-10-20	Downgrade	Raymond James	Strong Buy → Outperform
Nov-10-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-19-20	Initiated	The Benchmark Company	Buy
Feb-06-20	Initiated	Oppenheimer	Outperform
Nov-15-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-10-18	Resumed	BTIG Research	Buy
Sep-10-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-04-18	Initiated	H.C. Wainwright	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Mar-12-18	Downgrade	Wedbush	Outperform → Neutral
Feb-02-18	Initiated	Morgan Stanley	Overweight
Nov-28-17	Resumed	Piper Jaffray	Overweight
Oct-31-17	Initiated	Robert W. Baird	Outperform
Oct-27-17	Initiated	Canaccord Genuity	Buy
Oct-23-17	Reiterated	Stifel	Buy
Oct-12-17	Initiated	Raymond James	Outperform
Aug-17-17	Initiated	Evercore ISI	Outperform
Jul-28-17	Resumed	Stifel	Buy

View All

Voyager Therapeutics Inc Stock (VYGR) Latest News

Dec 12, 2025